Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA). Data from […]
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ESMO 2024
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, presentations on new and updated data from trials of zanidatamab at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain. New and updated data with longer follow-up, including overall survival findings, will be presented from an ongoing […]
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary […]
Introducing Pride in Biotech
We’re excited to launch Pride in Biotech, a Vancouver-based community to empower lesbian, gay, bisexual, transgender, and queer professionals in the drug development industry through networking, education, advocacy, professional development, and peer support. Brought to you by Zymeworks, the inaugural Pride in Biotech event is led by our ZYME&Proud team and will take place on […]
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). If […]
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
